Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GPR6 | P46095 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.30 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.30 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.30 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL5212428 | 0.91 | TACR1 (0.40) | TACR1SMN1; SMN2HSD17B10POLBGPR6 | |
| Triaziquone SCHEMBL5211799 | 0.88 | TACR1 (0.36) | TACR1POLBHRH3CACNA2D1CACNA1B | |
| Triaziquone SCHEMBL5210683 | 0.88 | TACR1 (0.35) | TACR1SMN1; SMN2POLBGPR6ALDH1A1 | |
| Triaziquone SCHEMBL5208749 | 0.86 | TACR1 (0.39) | TACR1SMN1; SMN2POLBGPR6ALDH1A1 | |
| Triaziquone SCHEMBL5209917 | 0.85 | TACR1 (0.39) | TACR1SMN1; SMN2POLBGPR6ALDH1A1 | |
| Triaziquone SCHEMBL5213272 | 0.84 | TACR1 (0.37) | TACR1POLBGPR6HRH3CACNA2D1 | |
| Triaziquone SCHEMBL5211670 | 0.84 | TACR1 (0.40) | TACR1POLBGPR6ALDH1A1HRH3 | |
| Triaziquone SCHEMBL5212997 | 0.83 | TACR1 (0.36) | TACR1POLBHRH3CACNA2D1CACNA1B | |
| Triaziquone SCHEMBL5212048 | 0.83 | TACR1 (0.36) | TACR1POLBHRH3CACNA2D1CACNA1B | |
| Trifluoroacetic Acid SCHEMBL5211806 | 0.79 | TACR1 (0.40) | TACR1SMN1; SMN2POLBALDH1A1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7183276-B2 | Azole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-27 | — | — | US | disclosed |
| US-20050090534-A1 | Azole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-28 | — | — | US | disclosed |
| EP-1486490-A1 | AZOLE COMPOUNDS | Takeda Chemical Industries, Ltd. (JP) | 2004-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090534-A1 | Azole compounds | AHR, NR0B2, NR2C2 | TACR1 2372/4885SMN1; SMN2 584/4885HSD17B10 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.